Novo Slides as Amgen Update Fuels Obesity Drug Competition Fears [BNN Bloomberg (Canada)]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: BNN Bloomberg
The stock fell as much as 4.9%, the most in six months, after Amgen Inc.'s chief executive officer said he was “very encouraged” by early results from a study of MariTide. That added to Thursday's 2.7% decline after the Danish drugmaker reported sales of its Wegovy weight-loss drug that missed analysts' elevated expectations. Optimism over soaring sales of the Wegovy and Ozempic drugs have seen Novo's market capitalization surpass $500 billion this year, reinforcing its position as Europe's most valuable listed company. The stock has more than quadrupled since the start of 2020. Amgen shares soared 13% in premarket trading on Friday following the comments from CEO Robert Bradway on a post-earnings conference call. Read: Amgen Soars After CEO Gives Update on Experimental Obesity Drug However, Barclays Plc analyst Emily Field said it's too early to judge the competitive threat to Novo or Eli Lilly & Co., maker of obesity treatment Zepbound. “As of today, we see no cause for c
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen Inc. (NASDAQ: AMGN) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $380.00 price target on the stock.MarketBeat
- Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]Yahoo! Finance
- AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCEPR Newswire
- Biosimilars Market Industry Report 2024 - Rising Demand for Biosimilars as a Cost-effective Alternative has Promoted the Need for Increased In-house Development and Outsourcing Operations [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 10/30/24 - Beat
AMGN
Sec Filings
- 11/6/24 - Form 4
- 11/6/24 - Form 4
- 11/6/24 - Form 4
- AMGN's page on the SEC website